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Excimer laser coronary atherectomy (ELCA) can be used during complex percutaneous coronary interventions (PCIs) 
to debulk and modify the tissue with photochemical, photothermal, and photokinetic mechanisms without causing sig-
nificant vessel injury. ELCA can facilitate treatment of balloon uncrossable, balloon undilatable, in-stent restenotic, 
saphenous vein graft and thrombotic lesions. Potential complications include perforation and dissection. Judicious use 
of ELCA can improve the outcomes of complex PCI.
Az­excimer­lézer­alkalmazása­perkután­koronáriaintervenció­során
Az excimer lézer koronáriaaterektómia (ELCA) komplex perkután koronáriaintervenciók (PCI) során alkalmazható plak-
kok módosítására, roncsolására, fotokémiai, fototermikus és fotokinetikai mechanizmus segítségével anélkül, hogy 
jelentősen károsítaná a koronária ép szöveteit. A lézer aterektómia elősegíti a ballonnal áthatolhatatlan, tágíthatatlan, a 
korábban implantált stentben resztenotikus, a vénagraft és trombotikus léziók kezelését. Potenciális komplikációk közt 
a koronáriaperforáció és disszekció említendő. Az ELCA körültekintő használatával a komplex koronáriaintervenciók 
hatékonyságát és biztonságát fokozhatjuk.
A kézirat 2020. 09. 30-án érkezett a szerkesztőségbe, 2020. 10. 05-én került elfogadásra.
Keywords: laser, percutaneous coronary intervention, complex coronary lesion
lézer, percutan koronariaintervenció, komplex koronárialézióKulcsszavak:
Introduction
Use of excimer laser coronary atherectomy (ELCA) has 
evolved over time and is currently used in complex per-
cutaneous coronary interventions (PCIs). The U.S. Food 
and Drug Administration (FDA) approved ELCA in 1992, 
and it is currently indicated for the following scenarios: 
occluded saphenous vein bypass grafts (SVG); long (>20 
mm in length) lesions; ostial lesions; moderately calcified 
lesions; eccentric lesions; chronic total occlusions cros-
sable with a guidewire; balloon refractory lesions; and 
in-stent restenosis (1). In this review we summarize the 
use of excimer laser in contemporary PCI.
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The basics
The term laser is derived from the acronym “Light Amp-
lification by Stimulated Emission of Radiation”, while the 
term excimer is derived from “excited dimer” (2). ELCA 
stimulates the electrons and elevates them to a higher 
energy level with electromagnetic energy. When the 
electrons return to their baseline energy level, protons 
are released, resulting in monochromatic light emissi-
on. ELCA applies a xenon-chloride (XeCl) excimer la-
ser to create bursts of ultraviolet light pulses at 308 na-
nometers with pulse frequency of 25-80 Hz and fluence 
of 30-80 mJ/mm2. Saline flush is essential during laser 
application to prevent a transient bubble phenomenon 
and to assist the laser to reach the tissue, since blood 
and contrast absorb 308 nm light avidly.(3) This was not 
implemented in early use of laser, which at least in part 
explains the high rate of complications such as dissec-
tion, abrupt vessel closure and spasm (4, 5).
Excimer laser ablates tissues in three ways: pho-
tochemical, photothermal and photokinetic. The pho-
tochemical mechanism means fracture of molecular 
bonds: the UV light pulse hits the plaque and is highly 
absorbed, with each photon carrying enough energy to 
break the bond. Second, the photothermal mechanism 
refers to tissue vaporization, where molecular bonds 
are vibrated during the absorption resulting in heat. The 
intracellular water is vaporized resulting in cell rupture 
and vapor bubble creation. The last mechanism is pho-
tokinetic, the quick expansion and collapse of the vapor 
bubbles helps break down the plaque, but also assi-
sts in clearing byproducts of ablation, such as gases 
and small particles. The majority of these particles are 
cleared by the reticuloendothelial system, decreasing 
the risk of distal embolization (2).
Currently the laser equipment used clinically is produced 
by Philips (formerly Spectranetics). The system includes 
a laser unit, which creates the laser beam and a series 
of catheters, which transmit the energy by fiber optics to 
the tip of the catheter and the target lesions. Laser cathe-
ters are available in various sizes (0.9 mm, 1.4 mm, 1.7 
mm and 2.0 mm in diameter) with both over-the-wire and 
rapid-exchange/monorail versions. There are also con-
centric and eccentric multifiber versions (2). Laser can be 
used with any 0.014” guidewire, which is a great advanta-
ge compared with other atherectomy techniques such as 
rotational and orbital atherectomy. For coronary catheters 
the device can be operated for 10 s (during this time 200 
individual laser pulses could be delivered), followed by a 5 
s rest period, while peripheral ELCA catheters can opera-
te continuously, without a resting period (3).
Clinical studies and current use of ELCA
Early studies with laser were performed before the 
stent era. Cook et al. showed that ELCA was an effec-
tive and safe treatment option for lesions identified as 
not ideal for balloon angioplasty in 1991 with 84% acute 
laser success and 94% procedural success. ELCA was 
also used in chronic total occlusions with 72% success 
(6). The Amsterdam-Rotterdam trial (AMRO) randomi-
zed 103 patients with >10 mm long functional or total 
coronary occlusions to laser vs. balloon angioplasty 
and showed angiographic success rates of 65% and 
61%, respectively, with similar incidence of complica-
tions (7). In the Excimer laser, Rotational atherectomy, 
and Balloon angioplasty Comparison (ERBAC) stu-
dy, published in 1997, 685 patients were randomized 
to one of the three treatment modalities: balloon angi-
oplasty, rotational atherectomy or excimer laser. Rota-
tional atherectomy demonstrated the highest success 
rates, but the incidence of restenosis was equally high 
with all three modalities. Nevertheless, these studies 
applied an old laser catheter type without saline flush 
and stenting was only performed in the ERBAC study 
when occlusive dissections could not be treated with 
prolonged balloon inflations (5). Following the develop-
ment of drug eluting stents and also due to high device 
cost, the use of laser decreased until recently, when 
ELCA re-emerged as an important treatment strategy 
for complex coronary lesions (8).
ELCA is often used in balloon undilatable lesions, whi-
ch are lesions that do not expand despite high-pressu-
re balloon inflations. These lesions can be treated with 
one or more buddy wires, cutting balloons, Angiosculpt, 
rotational atherectomy, orbital atherectomy, intravascu-
lar lithotripsy or laser (9). In a study by Fernandez et al, 
ELCA ± rotational atherectomy was used in 58 patients 
with balloon failure, including 22 patients with balloon 
undilatable lesions, 2 of whom (9%) had chronic total 
occlusions. All lesions were successfully treated; one 
case with rotational atherectomy and the other one with 
ELCA. In one CTO case a Type I (contained) perforation 
occurred without extravasation, related to subsequent 
balloon dilatation after ELCA use, and was successfully 
treated with drug-eluting stents (10). In the LEONARDO 
(early outcome of high energy Laser [Excimer] facilita-
ted coronary angioplasty ON hARD and complex cal-
cified and ballOon-resistant coronary lesions) registry, 
ELCA was used successfully in 30 of 32 (93.7%) bal-
loon failure cases without any major complications (11). 
The LAVA study (LAser Veterans Affairs) examined la-
ser use among veteran patients undergoing PCIs and 
demonstrated that balloon undilatable lesions were the 
second most common indication with laser use (40.8% 
of the cases) with high technical and procedural suc-
cess rates of 94.3% and 93.8% respectively (12).
Another possible application of laser is the dilation of in-
stent restenotic lesions. In this subgroup of lesions if the 
standard laser with saline flush fails, lasing during cont-
rast injections could be applied (Figure 1). This tech-
nique should be used only with 0.9 mm catheters and 
with great caution, as it can cause perforations or vessel 
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FIGURE 1. Laser coronary atherectomy during contrast injection for treating an under-expanded stent
PANEL A: Coronary angiography demonstrating a long calcified right coronary artery lesion
PANEL B: Stent underexpansion (arrows)
PANEL C: Waist in postdilation balloon (arrow) in spite of high pressure inflation and use
of a buddy guidewire (arrowhead)
PANEL D: Stent expansion after activation of laser during contrast injection
PANEL E: Intravascular ultrasonography demonstrating good stent expansion (minimal lumen area: 8.2 mm2)
PANEL F: Optical coherence tomography demonstrating good stent expansion with extensive sub-stent dissections.
Figure reproduced from “JACC Cardiovascular Interventions” with permission.
407
Cardiologia Hungarica Karácsonyi et al. Excimer Laser Use in Percutaneous Coronary Intervention
dissections from the rapidly exploding bubbles (13–15). 
In the ELLEMENT (Excimer Laser Lesion Modification 
to Expand Non-dilatable sTents) registry 28 undilatable 
stented coronary lesions were treated with laser using 
the following technique: if non-compliant balloon predi-
lation was unsuccessful, ELCA was applied with gradual 
increase of the fluency and repetition rates. If optimal 
stent expansion could not be achieved, laser was per-
formed with contrast injection at the highest fluency and 
repetition rates (80 mJ/mm2 and 80 Hz using the 0.9 
mm catheter). Laser-assisted stent dilatation was suc-
cessfully achieved in 96.4%, periprocedural myocardial 
infarction occurred in 7.1%, transient slow-flow in 3.6% 
and ST-segment elevation in 3.6% (16).
Balloon uncrossable lesions can be challenging to treat 
and are defined as lesions that cannot be crossed with 
a balloon after successful guidewire crossing (Figure 
2). These lesions are relatively common: they repre-
sented 6.4%, 24 of 373 consecutive CTO lesions in a 
single center study (in this series ELCA was used in 
8.7% of the cases) (17) and 9%, 63 of 718 lesions in 
a multicenter CTO registry (ELCA was used in 18% of 
the lesions) (18). In the previously mentioned study by 
Fernandez et al, ELCA was used in 36 patients with 
balloon uncrossable lesions. Among these patients, 16 
were CTOs (44%) and procedural success was achie-
ved in 13 (81%), with one patient developing transient 
no reflow. The other 20 lesions were in non-occlusive 
lesions and ELCA use was associated with procedural 
success in 17 (85%) of them. Ten lesions were only 
treated with ELCA, whereas both ELCA and rotational 
atherectomy were used in the remaining 7 lesions (10). 
In the Laser Veterans Affair (LAVA) multicenter registry 
enrolled 130 target lesions in 121 consecutive PCIs, the 
most common indication for ELCA was balloon uncro-
ssable lesions (43.8%) with technical success of 87.8% 
and procedural success of 83.7%. (13) Laser can be 
combined in balloon uncrossable lesions with rotational 
atherectomy (“RASER” technique): ELCA is first used 
to cross the lesion and facilitates the passing of a ro-
tational atherectomy wire followed by rotablation (19).
In addition to the previous applications, ELCA can be 
a valuable tool in management of intracoronary throm-
bus (Figure 3). Laser can induce shock waves that can 
separate thrombi from the vessel wall, so it can facili-
tate adjunctive thrombectomy (20). Furthermore ELCA 
also inhibits aggregation of platelets (“stunned platelet 
phenomenon”) (21) and it can create photoacoustic dis-
solution of fibrin clots (22). The Cohort of Acute Re-
vascularization in Myocardial Infarction with Excimer 
Laser (CARMEL) multicenter registry included 151 AMI 
patients (54% Q wave and 46% non-Q wave), several 
of whom had high-risk characteristics, such as car-
diogenic shock (13%) and saphenous vein graft as the 
target lesion (21%). Laser use was successful in 95% 
of the cases with 91% overall procedural success; the 
largest effect on luminal enlargement was among ca-
ses with large thrombus burden. Dissection occurred 
in 5%, perforation in 0.6%, distal vessel occlusion in 
0.6%, and distal embolization in 2% (23).
FIGURE 2. Use of ELCA in a balloon uncrossable chronic total 
occlusion. A 65-year-old man with history of diabetes and hyper-
tension was referred for treatment of a left anterior descending 
artery (LAD) chronic total occlusion (CTO) (arrow, PANEL A). The 
left main was engaged with an 8 French (Fr) XB 3.5 guide cathe-
ter and the right coronary artery was engaged with a 6 Fr diag-
nostic catheter. Antegrade crossing was attempted using a Fiel-
der XT (Asahi Intecc) and Cross-It (Abbott Vascular) guidewires 
without success (arrow, PANEL B). A Pilot 200 guidewire (Abbott 
Vascular) with the support of an OTW balloon crossed the lesion; 
however, no other balloon nor the CrossBoss catheter (Boston 
Scientific) could cross the lesion. ELCA was used (arrow, PANEL 
C), successfully crossing the mid-LAD CTO. After balloon pre-
dilation, four drug-eluting stents were deployed (arrow, PANEL 
D) with an excellent final result (PANEL E) and no complications. 
Figure reproduced from “Textbook of Atherectomy” with the 
permission of Dr. Nicolas Shammas.
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ELCA can also be used in saphenous vein graft (SVG) 
lesions that often have large thrombus burden with high 
risk of distal embolization and in-stent restenosis. Eber-
sole et al enrolled 31 patients for laser angioplasty who-
se infarct related vessel was a SVG. Device success 
rate was 87%, angiographic success rate was 97%, 
and the overall procedural success rate was 84%. The-
re were 3 cases of dissection (10%), one caused by 
the guidewire and 2 by the laser, and 3 cases of no 
reflow (one laser induced, one due to stent, and one 
due to use of a transluminal extraction catheter). The-
re were no acute closures, distal embolization of per-
forations (24). In the “Coronary graft Results following 
Atherectomy with Laser” (CORAL) multicenter regist-
ry 98 patients with >50% SVG stenosis were treated 
with ELCA. Inclusion and exclusion criteria in this study 
were aligned to those in the saphenous vein graft Angi-
oplasty Free of Emboli Randomized (SAFER) trial. The 
CORAL trial found that patients treated with laser had 
similar rates of no reflow (5.1% vs. 3%, p=0.37) and ab-
rupt closure (3.0% vs. 1.7%, p=0.40), but higher 30-day 
incidence of major adverse cardiac events (18.4% vs. 
9.6%, p=0.02) as compared with patients who received 
an embolic protection device in the SAFER trial (8, 25). 
ELCA may, therefore, be useful in SVG lesions especi-
ally when embolic protection device use is not feasible.
In highly complex lesions, such as CTOs ELCA could 
facilitate crossing of an “impenetrable proximal cap” 
after withdrawing the guidewire (26). This technique 
should be applied only by experienced operators, as 
FIGURE 3. Use of ELCA to treat intracoronary thrombus. A 67-year-old man with a history of hypertension, peripheral arterial 
disease, and smoking presented with inferior ST-segment elevation acute myocardial infarction. After aspirin and clopidogrel 
preloading, coronary angiography revealed moderate stenosis of the left anterior descending artery (LAD) and the circumflex 
artery (Cx) and thrombotic occlusion of right coronary artery (RCA). The RCA was engaged with a 6 French JR 4 guide and the 
distal RCA was wired successfully with a 0.014-inch guidewire. In spite of several rounds of aspiration thrombectomy and pre-
dilation with a 2.0×30 mm balloon (arrow, PANEL B), significant thrombus burden remained (arrow, PANEL C). Thrombectomy 
was repeated through a 6 French guide catheter extension without success. Intravascular ultrasound confirmed intraluminal 
wire position and large thrombus burden. ELCA using a 0.9-mm Turbo-Elite catheter (arrow, PANEL D) was performed (fluency 
80 mJ/mm2 and frequency 80 Hz) with some improvement (arrow, PANEL E). The 6 Fr right radial access was converted to 8 
Fr left femoral followed by repeat aspiration through an 8 Fr guide catheter extension and lasing with significant flow impro-
vement and resolution of intracoronary thrombus. After implantation of 3 overlapping drug-eluting stents, TIMI 3 flow was 
restored with 0% residual stenosis (PANEL F). The patient had an uneventful recovery. Figure reproduced from “Textbook of 
Atherectomy” with the permission of Dr. Nicolas Shammas
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it carries risk of perforation. The laser should only be 
advanced for a very short distance (0.5 mm or less) to 
modify the proximal cap enough to allow subsequent 
guidewire penetration (8, 9).
Conclusions
ELCA can facilitate treatment of complex coronary 
lesions, such as balloon uncrossable and undilatable 
lesions, highly thrombotic and SVG lesions. Meticulous 
attention to optimal technique is necessary to achieve 
the best possible clinical outcomes.
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